Literature DB >> 16283565

Preoperative steroid-related complications in Japanese pediatric patients with ulcerative colitis.

Keiichi Uchida1, Toshimitsu Araki, Yuji Toiyama, Shigeyuki Yoshiyama, Mikihiro Inoue, Hiroki Ikeuchi, Hidenori Yanagi, Chikao Miki, Takehira Yamamura, Masato Kusunoki.   

Abstract

PURPOSE: This study was designed to clarify a limit for steroid therapy in patients with ulcerative colitis through analyzing the preoperative major steroid-related complications and to define when alternative therapies, including surgery, should be performed in pediatric ulcerative colitis patients.
METHODS: The medical records of 28 pediatric and 57 adult patients with ulcerative colitis who underwent total proctocolectomy and ileal J-pouch-anal anastomosis were reviewed. The relationship between the preoperative dose of glucocorticoids and major steroid-related complications, as well as the surgery variables, was evaluated.
RESULTS: Significantly higher incidences of growth retardation, osteoporosis, glaucoma, and cataracts were noted in pediatric patients than in adult patients. In pediatric patients, major steroid-related complications occurred at a significantly lower preoperative total dosage of glucocorticoids/body weight (mg/kg) or preoperative total dosage of glucocorticoids/body surface area (mg/m2) than in adult patients. A similar surgical procedure was performed in both pediatric and adult patients. The presence of major steroid-related complications can lower a patient's long-term quality of life.
CONCLUSIONS: Evidence-based guidelines for the recommended dose of glucocorticoids according to body weight or body surface area are needed. To allow patients to feel well and maintain a good quality of life, early introduction of alternative treatments, including surgery, should be considered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16283565     DOI: 10.1007/s10350-005-0213-7

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  7 in total

1.  Immunosuppressive medication is not associated with surgical site infection after surgery for intractable ulcerative colitis in children.

Authors:  Keiichi Uchida; Yoshikazu Ohtsuka; Atsushi Yoden; Hitoshi Tajiri; Hideaki Kimura; Takashi Isihige; Hiroyuki Yamada; Katsuhiro Arai; Takeshi Tomomasa; Kosuke Ushijima; Tomoki Aomatsu; Satoru Nagata; Kohei Otake; Kohei Matsushita; Mikihiro Inoue; Takahiro Kudo; Kenji Hosoi; Kazuo Takeuchi; Toshiaki Shimizu
Journal:  Intractable Rare Dis Res       Date:  2017-05

2.  A retrospective comparison of outcomes for open vs. laparoscopic surgical techniques in pediatric ulcerative colitis.

Authors:  Brent A Willobee; Jennifer A Nguyen; Anthony Ferrantella; Hallie J Quiroz; Anthony R Hogan; Ann-Christina Brady; Samir Pandya; Amber H Langshaw; Juan E Sola; Chad M Thorson; Eduardo A Perez
Journal:  Transl Gastroenterol Hepatol       Date:  2021-07-25

Review 3.  History of and current issues affecting surgery for pediatric ulcerative colitis.

Authors:  Keiichi Uchida; Toshimitsu Araki; Masato Kusunoki
Journal:  Surg Today       Date:  2012-12-01       Impact factor: 2.549

Review 4.  Late consequences of chronic pediatric illness.

Authors:  Susan Turkel; Maryland Pao
Journal:  Psychiatr Clin North Am       Date:  2007-12

5.  Gender May Influence the Immunosuppressive Actions of Prednisone in Young Patients With Inflammatory Bowel Disease.

Authors:  Marianna Lucafò; Matteo Bramuzzo; Davide Selvestrel; Prisca Da Lozzo; Giuliana Decorti; Gabriele Stocco
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

6.  Sequential Epiphyseal Cartilage Changes of Femoral Heads in C57BL/6 Female Mice Treated with Excessive Glucocorticoids.

Authors:  Shengyang Jin; Liang Yang; Chunqing Meng; Yu He; Kaige Ma; Wei Huang; Hong Wang
Journal:  Cartilage       Date:  2020-12-03       Impact factor: 3.117

7.  Pediatric ulcerative colitis: current treatment approaches including role of infliximab.

Authors:  Gia M Bradley; Maria Oliva-Hemker
Journal:  Biologics       Date:  2012-06-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.